UCB (OTCMKTS:UCBJF) Shares Gap Up – What’s Next?

UCB SA (OTCMKTS:UCBJF) shares gapped up before the market opened on Wednesday. The stock had previously closed at $237.84, but opened at $250.34. UCB shares last traded at $250.34, with a volume of 52 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Piper Sandler restated a “neutral” rating on shares of UCB in a report on Wednesday, July 22nd. Jefferies Financial Group upgraded shares of UCB to a “hold” rating in a report on Monday, August 3rd. Finally, Stephens reaffirmed an “overweight” rating on shares of UCB in a research note on Wednesday. Five investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy”.

UCB Price Performance

The business has a 50 day moving average of $248.16 and a two-hundred day moving average of $275.41. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

About UCB

UCB is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for people living with severe diseases. Its primary therapeutic areas are neurology and immunology, with research activities spanning conditions such as epilepsy, myasthenia gravis, Parkinson’s disease, psoriasis, psoriatic arthritis, axial spondyloarthritis and other immune-mediated disorders.

The company’s medicines include Bimzelx (bimekizumab), an immunology treatment; Cimzia (certolizumab pegol), used for several inflammatory conditions; and a portfolio of neurological therapies that includes Briviact (brivaracetam), Keppra (levetiracetam), Fintepla (fenfluramine) and Nayzilam (midazolam).